Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Journal of Environmental Pathology, Toxicology and Oncology
Fator do impacto: 1.625 FI de cinco anos: 1.63 SJR: 0.402 SNIP: 0.613 CiteScore™: 2.3

ISSN Imprimir: 0731-8898
ISSN On-line: 2162-6537

Journal of Environmental Pathology, Toxicology and Oncology

DOI: 10.1615/JEnvironPatholToxicolOncol.v28.i1.40
pages 39-46

The Cyclooxygenase-2 Inhibitor Etoricoxib Is a Potent Chemopreventive Agent of Colon Carcinogenesis in the Rat Model

Manpreet Kaur Saini
Department of Biophysics, Panjab University, Chandigarh-160014, India
Pinky Sharma
Department of Biophysics, Panjab University, Chandigarh-160014, India
Jasmeet Kaur
Department of Biophysics, Panjab University, Chandigarh-160014, India
Sankar Nath Sanyal
Department of Biophysics, Panjab University, Chandigarh, India 160014

RESUMO

Cyclooxygenase-2 (COX-2), an inducible prostaglandin G/H synthase, is overexpressed in several human cancers, including colon cancer, and therefore the potential ability of a selective COX-2 inhibitor, etoricoxib, is considered in the prevention of the 1,2-dimethyl hydrazine (DMH)-induced colon carcinogenesis in the rat model. DMH was injected s.c. for 6 weeks, whereas etoricoxib was fed orally to the rats on a daily basis. The results showed that DMH produced a very high number of multiple plaque lesions (MPLs), putative neoplastic biomarkers, localized throughout the colon, whereas considerable regression was observed with etoricoxib treatment. In addition, the etoricoxib group was the only group that exhibited very few of these lesions. Histopathological analysis revealed extreme dysplasia, a few adenomas, and other carcinogenic changes in the DMH group, which are distinctly absent in the etoricoxib-treated group. COX-2 was also seen to be highly expressed following DMH treatment. The DMH treatment caused very few apoptotic cells, as determined by the TUNEL assay of the colonic mucosa in paraffin sections whose number greatly increased following etoricoxib treatment. Because all these changes were clearly reversed by etoricoxib in DMH-treated animals, and the use of etoricoxib alone did not produce a neoplastic effect per se, it appears that etoricoxib, a selective COX-2 inhibitor, might be a safe and potentially chemopreventive agent in colon cancer.


Articles with similar content:

Induction of Apoptosis as a Potential Chemopreventive Effect of Dual Cycloxygenase Inhibitor, Diclofenac, in Early Colon Carcinogenesis
Journal of Environmental Pathology, Toxicology and Oncology, Vol.29, 2010, issue 1
Sankar Nath Sanyal, Jasmeet Kaur
Role of Zinc in Modulating Histoarchitectural and Biochemical Alterations During Dimethylhydrazine (DMH)-Induced Rat Colon Carcinogenesis
Journal of Environmental Pathology, Toxicology and Oncology, Vol.28, 2009, issue 4
Devinder K. Dhawan, Anshoo Malhotra, Vijayta Dani Chadha, Praveen Nair
Celecoxib Targeted Therapy Attenuates Mouse Colon Carcinogenesis through Modulation of Expression Patterns of Cancer Stem Cells
Journal of Environmental Pathology, Toxicology and Oncology, Vol.38, 2019, issue 4
Elsayed I. Salim, Eman A. Eltonouby, Jin Seok Kang, Magdy E. Mahfouz, Mona M. Hegazi, Hager M. Helmy
Chemoprevention of Colon Cancer through Inhibition of Angiogenesis and Induction of Apoptosis by Nonsteroidal Anti-Inflammatory Drugs
Journal of Environmental Pathology, Toxicology and Oncology, Vol.35, 2016, issue 3
Sankar Nath Sanyal, Preety Ghanghas, Chandan Rana, Shelly Jain
Vicenin-2 Treatment Attenuated the Diethylnitrosamine-Induced Liver Carcinoma and Oxidative Stress through Increased Apoptotic Protein Expression in Experimental Rats
Journal of Environmental Pathology, Toxicology and Oncology, Vol.39, 2020, issue 2
Guojin Gong, Vishnu Priya Veeraraghavan, Yuhui Chen, Yandong Li, Chunyang Zhang, Ming Zhang, Srinivasa Rao Bolla, Chunni Xu